348 related articles for article (PubMed ID: 36639130)
1. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R
Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130
[TBL] [Abstract][Full Text] [Related]
2. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
3. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS;
JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567
[TBL] [Abstract][Full Text] [Related]
4. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
[TBL] [Abstract][Full Text] [Related]
5. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
6. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R; Filippatos G; Pitt B; Anker SD; Rossing P; Joseph A; Kolkhof P; Nowack C; Gebel M; Ruilope LM; Bakris GL;
Eur Heart J; 2022 Feb; 43(6):474-484. PubMed ID: 35023547
[TBL] [Abstract][Full Text] [Related]
8. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
Bakris GL; Ruilope LM; Anker SD; Filippatos G; Pitt B; Rossing P; Fried L; Roy-Chaudhury P; Sarafidis P; Ahlers C; Brinker M; Joseph A; Lawatscheck R; Agarwal R;
Kidney Int; 2023 Jan; 103(1):196-206. PubMed ID: 36367466
[TBL] [Abstract][Full Text] [Related]
9. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
Filippatos G; Anker SD; Pitt B; McGuire DK; Rossing P; Ruilope LM; Butler J; Jankowska EA; Michos ED; Farmakis D; Farjat AE; Kolkhof P; Scalise A; Joseph A; Bakris GL; Agarwal R
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):85-93. PubMed ID: 36251465
[TBL] [Abstract][Full Text] [Related]
10. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
Bansal S; Canziani MEF; Birne R; Anker SD; Bakris GL; Filippatos G; Rossing P; Ruilope LM; Farjat AE; Kolkhof P; Lage A; Brinker M; Pitt B
BMJ Open; 2024 Mar; 14(3):e076444. PubMed ID: 38508632
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
13. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
14. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
[TBL] [Abstract][Full Text] [Related]
15. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
Rosas SE; Ruilope LM; Anker SD; Pitt B; Rossing P; Bonfanti AAC; Correa-Rotter R; González F; Munoz CFJ; Pergola P; Umpierrez GE; Scalise A; Scott C; Lawatscheck R; Joseph A; Bakris GL;
Kidney Med; 2023 Oct; 5(10):100704. PubMed ID: 37745646
[TBL] [Abstract][Full Text] [Related]
16. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
Ruilope LM; Pitt B; Anker SD; Rossing P; Kovesdy CP; Pecoits-Filho R; Pergola P; Joseph A; Lage A; Mentenich N; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2023 Feb; 38(2):372-383. PubMed ID: 35451488
[TBL] [Abstract][Full Text] [Related]
17. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
Flack JM; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Adler SG; Fried L; Jamerson K; Toto R; Brinker M; Farjat AE; Kolkhof P; Lawatscheck R; Joseph A; Bakris GL;
Kidney Med; 2023 Dec; 5(12):100730. PubMed ID: 38046911
[TBL] [Abstract][Full Text] [Related]
18. Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
Koya D; Anker SD; Ruilope LM; Rossing P; Liu Z; Lee BW; Lee CT; Scott C; Kolkhof P; Lawatscheck R; Wang L; Joseph A; Pitt B;
Am J Nephrol; 2023; 54(9-10):370-378. PubMed ID: 37708857
[TBL] [Abstract][Full Text] [Related]
19. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
[TBL] [Abstract][Full Text] [Related]
20. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]